Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
W.F. Balistreri.
Liver disease in infancy and childhood.
Schiff’s diseases of the liver, 8th ed, pp. 1357-1512
[2.]
J. Manzanares, P. Urruzuno, E. Medina.
Tratamiento médico del niño con enfermedad colestática crónica. Soporte nutricional y tratamiento sustitutivo.
An Esp Pediatr, 116 (1998), pp. 18-21
[3.]
R.I.G. Holt, J.S. Jones, A.J. Baker, C.R. Buchanan, J.P. Miell.
The effect of short stature, portal hypertension and cholestasis on growth hormone resistance in children with liver disease.
J Clin Endocrinol Metab, 84 (1999), pp. 3277-3282
[4.]
R.J. Sokol, C. Stall.
Anthropometric evaluation of children with chronic liver disease.
Am J Clin Nutr, 52 (1990), pp. 203-208
[5.]
V. Ramaccioni, H.E. Soriano, R. Arumugam, W.J. Klish.
Nutritional aspects of chronic liver disease and liver transplantation in children.
J Pediatr Gastroenterol Nutr, 30 (2000), pp. 361-367
[6.]
P. Roggero, E. Cataliotti, L. Ulla, S. Stuflesser, G. Nebbia, D. Bracaloni.
Factors influencing malnutrition in children waiting for liver transplants.
Am J Clin Nutr, 65 (1997), pp. 1852-1857
[7.]
S.E. Chin, R.W. Sheppherd, B.J. Thomas, G.J. Cleghorn, M.K. Patrick, J.A. Wilcox.
The nature of malnutrition in children whith end-stage liver disease awaiting orthotopic liver transplantation.
Am J Clin Nutr, 56 (1992), pp. 164-168
[8.]
P. Socha, B. Koletzko, E. Swiatowska, J. Pawlowska, A. Stolarczyk, J. Socha.
Essential fatty acid metabolism in infants with cholestasis.
Acta Paediatr, 87 (1998), pp. 278-283
[9.]
A.A. Moukarzel, I. Najm, J. Vargas, S.V. McDiarmid, R.W. Busuttil, M.E. Ament.
Effects of nutritional status on outcome of orthotopic liver transplantation in pediatric patients.
Tansplant Proc, 22 (1990), pp. 1560-1563
[10.]
P. Jara, L. Hierro.
Nutrición y enfermedad hepatobiliar.
Tratado de nutrición pediátrica, 1st ed, pp. 825-833
[11.]
O. Bernard, M. Hadchouel.
Paediatric liver disease.
Oxford textbook of clinical hepatology, 2nd ed, pp. 1877-1899
[12.]
M. Duché, D. Habès, A. Lababidi, C. Chardot, J. Wenz, O. Bernard.
Percutaneous gastrostomy for continous feeding in children with chronic cholestasis.
J Pediatr Gastoenterol Nutr, 29 (1999), pp. 42-45
[13.]
S.S. Kaufman, D.J. Scrivner, N.D. Murray, J.A. Vanderhoof, M.H. Hart, D.L. Antonson.
Influence of Portagen and Pregestimil on essential fatty acid status in infantile liver disease.
Pediatrics, 89 (1992), pp. 151-154
[14.]
R.J. Sokol.
Fat-soluble vitamins and their importance in patients with cholestasis liver diseases.
Gastroenterol Clin North Am, 23 (1994), pp. 673-705
[15.]
D. Gleeson, J.L. Boyer.
Intrahepatic cholestasis.
Oxford textbook of clinical hepatology, 2nd ed, pp. 1591-1620
[16.]
R.J. Sokol, N. Butler-Simon, C. Conner, J.E. Heubi, F.R. Sinatra, F.J. Suchy.
Multicenter trial of d-a-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin deficiency in children with chronic cholestasis.
Gastroenterology, 104 (1993), pp. 1727-1735
[17.]
P. Socha, B. Koletzko, J. Pawlowska, K. Proszynska, J. Socha.
Treatment of cholestatic children with water-soluble vitamin E (a-tocopheryl polyethylene glycol succinate): effects on serum vitamin E lipid peroxides, and polyunsatured fatty acids.
J Pediatr Gastroenterol Nutr, 24 (1997), pp. 189-193
[18.]
E.A. Argao, J.E. Heubi, B.W. Hollis, R.C. Tsang.
D-alpha-tocopheryl polyethylene glycol-1000 succinate enhances the absorption of vitamin D in chronic cholestatic liver disease of infancy and childhood.
Pediatr Res, 31 (1992), pp. 146-150
[19.]
J.E. Heubi, J.V. Higgins, E.A. Argao, R.I. Sierra, B.L. Specker.
The role of magnesium in the pathogenesis of bone disease in childhood cholestatic liver disease: A preliminary report.
J Pediatr Gastroenterol Nutr, 25 (1997), pp. 301-306
[20.]
E.A. Jones, N.V. Bregaza.
The pruritus of colestasis.
Hepatology, 29 (1999), pp. 1003-1006
[21.]
A. Parés, N. Guañabens.
Prurito y osteopenia en la colestasis.
Tratamiento de las enfermedades hepáticas, 1. ed, pp. 133-140
[22.]
W.F. Balistreri.
Bile acid therapy in pediatric hepatobiliary disease: The role of ursodeoxycholic acid.
J Pediatr Gastroenterol Nutr, 24 (1997), pp. 573-589
[23.]
B. Yerushalmi, R.J. Sokol, M.R. Narkewicz, D. Smith, F.M. Karrer.
Use of rifampin for severe pruritus in children with chronic cholestasis.
J Pediatr Gastroenterol Nutr, 29 (1999), pp. 442-447
[24.]
G.V. Gregorio, C.S. Ball, A.P. Mowat, G. Mieli-Vergani.
Effect of rifampicin in the treatment of pruritus in hepatic cholestasis.
Arch Dis Child, 69 (1993), pp. 141-143
[25.]
M.I. Prince, A.D. Burt, D.E. Jones.
Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.
Gut, 50 (2002), pp. 436-439
[26.]
V. Lee, F.C. Ryckman, G. Porta, I. Miura, E. De Carvalho, M. Servidoni.
Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis.
J Pediatr Gastroenterol Nutr, 30 (2000), pp. 152-156
[27.]
K.M. Emerick, P.F. Whitington.
Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome.
Hepatology, 35 (2002), pp. 1501-1506
[28.]
H. Schworer, H. Hartmann, G. Ramadory.
Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists; effectiveness of ondansetron.
Pain, 61 (1995), pp. 33-37
[29.]
C. Muller, S. Pongratz, J. Pidlich, E. Penner, A. Kaider, M. Schemper.
Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: A randomized, placebo-controlled, double bind cross-over trial.
Eur J Gastro Hepatol, 10 (1998), pp. 865-870
Copyright © 2003. Asociación Española de Pediatría
